Advanced Analytical

AATI’s own Steve Siembieda, Vice President of Commercialization, recently penned a commentary in DDNews on two primary issues in CRISPR genome editing: (1) low specificity and (2) low efficiency.  Put simply, CRISPR technology produces too many off-target mutations and does not have the success rate necessary for adoption into sensitive applications, notably the treatment of genetic illnesses.  The article went on to discuss potential remedies for low specificity and low efficiency in CRISPR workflows and the associated QC and mutation screening challenges.  The Fragment Analyzer supports these remedies and fulfills the QC and screening needs of CRISPR pipelines, accurately assessing the suitability of reagents and identifying and characterizing positive lines.

Advanced Analytical Technologies, Inc (AATI) is excited to partner with Illumina to support collaborations and co-marketing activities involving our Fragment Analyzer™ Automated CE Systems for quality assessment of nucleic acids in Illumina next-generation sequencing (NGS) workflows. Assessing nucleic acid quality is essential for the success of NGS applications. The Fragment Analyzer provides a scalable method, tested by Illumina, for accurate analysis of a broad range of sample types in Illumina NGS library prep workflows, including genomic DNA, RNA, cell-free liquid biopsy, single-cell isolates, and prepared libraries before sequencing. Illumina has published an Application Note that provides an overview o

On the heels of opening Advanced Analytical SARL in France last year, AATI is thrilled to announce the opening of our third international office.  Located approximately 40 miles northwest of London in Milton Keynes, England, the AATI UK office will provide direct sales and support to the entire United Kingdom.  With the opening of the latest international office, AATI now provides direct sales and support to 10 countries, continuing our dedication to providing our customers with a world class experience.